Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01319929 | A Study of LY2828360 in Patients With Osteoarthritic Knee Pain | PHASE2 | COMPLETED | 39 | — | — | Mar 1, 2011 | Sep 1, 2011 | May 19, 2020 | 1 | Denmark |
The weekly mean of the 24-Hour APS was calculated from participants' daily entries for 24-hour average pain rating on an 11-point scale with scores from 0 (no pain) to 10 (worst possible pain). Data were recorded twice a day at approximately the same time each day, preferably first thing in the morning and in the afternoon.
| Arm | Type | Description |
|---|---|---|
| LY2828360 then Placebo | EXPERIMENTAL | 80 milligrams (mg) of LY2828360 daily by mouth for 4 weeks: placebo daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments. |
| Placebo then LY2828360 | EXPERIMENTAL | Placebo daily by mouth for 4 weeks: LY2828360 daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments. |
| Name | Type | Description |
|---|---|---|
| LY2828360 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Are male or female participants with osteoarthritis (OA), as determined by medical history and physical examination. Males and females with stable medical problems that, in the investigator's opinion, will not significantly alter the disposition of the drug, will not place the...